Diffuse hair loss in women: causes and therapeutic approach
https://doi.org/10.21518/2079-701X-2020-12-60-63
Abstract
Throughout human history, women have paid great attention to the beauty of their hair, and modern women are no exception. About 63% of young American women use different nutritional supplements to prevent hair loss. Diffuse hair loss is quite common in women and can occur against the background of various events: pregnancy, pre- and post-menopause, chronic diseases, etc. The most common is telogen effluvium (TE), which begins 2-3 months after the trigger event. Usually, TE process stops on its own, but can also become chronic. For many women, pregnancy and associated psycho-emotional stress become the triggering event, and in 75% of cases hair loss can become chronic.
In fact, TE is a violation of the hair growth cycle. First of all, it is necessary to exclude the trigger factor from the patient's life and only then to start normalizing the hair growth cycle and improve the quality of hair follicle nutrition. The most effective topical remedy for the treatment of diffuse hair loss is minoxidil. The reasons for its clinical effectiveness have not been fully studied, but it is known that it prolongs the hair growth phase. Unfortunately, after cancellation of the drug, hair loss is often renewed. Avoiding these effects is possible with a comprehensive approach to therapy. Inclusion of additional components in the therapy scheme, such as vitamin and mineral complexes, growth stimulants, specialized care products, allows to maintain and improve the results of treatment with minoxidil.
About the Authors
O. O. Melnichenko
Moscow Scientific and Practical Center of Dermatovenerology and Cosmetology
Russian Federation
Russian Federation
Olga O. Melnichenko - Cand. of Sci. (Med.), Dermatovenerologist, Moscow Scientific and Practical Center of Dermatovenerology and Cosmetology of the Moscow City Healthcare Department.
20, Seleznevskaya St., Moscow, 127473.
A. L. Piruzyan
Center for Theoretical Problems of Physicochemical Pharmacology of the Russian Academy of Sciences
Russian Federation
Russian Federation
Anastas L. Piruzyan - Dr. of Sci. (Med.), Professor, Chief Researcher, Center for Theoretical Problems of Physicochemical Pharmacology of the Russian Academy of Sciences.
30, Srednaya Kalitnikovskaya St., Moscow, 109029.
I. M. Korsunskaya
Center for Theoretical Problems of Physicochemical Pharmacology of the Russian Academy of Sciences
Russian Federation
Russian Federation
Irina M. Korsunskaya - Dr. of Sci. (Med.), Professor, Head of Laboratory, Center for Theoretical Problems of Physicochemical Pharmacology RAS.
30, Srednyaya Kalitnikovskaya St., Moscow, 109029.
References
1. Burns L.J., Senna M.M. Supplement use among women experiencing hair loss. Int J Womens Dermatol. 2020;6(3):211. doi: 10.1016/j.ijwd.2020.01.002.
2. Deo K., Sharma Y.K., Wadhokar M., Tyagi N. Clinicoepidemiological Observational Study of Acquired Alopecias in Females Correlating with Anemia and Thyroid Function. Dermatology Research and Practice. 2016;2016:6279108. doi: 10.1155/2016/6279108.
3. Vary J.C. Selected Disorders of Skin Appendages - Acne, Alopecia, Hyperhidrosis. Medical Clinics of North America. 2015;99(6):1195-1211. doi: 10.1016/j.mcna.2015.07.003.
4. Vary J.C., O'Connor K.M. Common Dermatologic Conditions. Medical Clinics of North America. 2014;98(3):445-485. doi: 10.1016/j.mcna.2014.01.005.
5. Rasheed H., Mahgoub D., Hegazy R., El-Komy M., Abdel Hay R., Hamid M.A., Hamdy E. Serum Ferritin and Vitamin D in Female Hair Loss: Do They Play a Role? Skin Pharmacol Physiol. 2013;26(2):101-107. doi: 10.1159/000346698.
6. Brenner F.M., Oldoni C. Telogen effluvium x female pattern hair loss: is there correlation? An Bras Dermatol. 2019;94(4):486-487. doi: 10.1590/abd1806-4841.20198427.
7. Rook A., Dawber R. (eds.) Diseases of the Hair and Scalp. Oxford, UK: Blackwell Science Publications; 1982.
8. Poonia K., Thami G.P., Bhalla M., Jaiswal S., Sandhu J. NonScarring Diffuse Hair Loss in Women: a Clinico-Etiological Study from tertiary care center in North-West India. J Cosmet Dermatol. 2019;18(1):401-407. doi: 10.1111/jocd.12559.
9. Gadzhigoroeva A.G. Minoxidil: a final judgment or a hope? Klinicheskaya dermatologiya i venerologiya = Russian Journal of Clinical Dermatology and Venereology. 2016;(4):96-101. (In Russ.) doi: 10.17116/klinder-ma201615496-101.
10. Blume-Peytavi U., Hillmann K., Dietz E., Canfield D., Garcia Bartels N. A randomized, single-blind trial of 5% minoxidil foam once daily versus 2% minoxidil solution twice daily in the treatment of androgenetic alopecia in women. J Am Acad Dermatol. 2011;65(6):1126-1134.e2. doi: 10.1016/j.jaad.2010.09.724.
11. Dhurat R., Sukesh MS, Avhad G., Dandale A., Pal A., Pund P. A randomized evaluator blinded study of effect of microneedling in androgenetic alopecia: a pilot study. Int J Trichology. 2013;5(1):6-11. doi: 10.4103/09747753.114700.
12. Yi Y., Li X., Jia J., Guy Didier D.N., Qui J., Fu J. et al. Effect of behavioral factors on severity of female pattern hair loss: an ordinal logistic regression analysis. Int J Med Sci. 2020;17(11):1584-1588. doi: 10.7150/ijms.45979.
Review
For citations:
Melnichenko OO, Piruzyan AL, Korsunskaya IM. Diffuse hair loss in women: causes and therapeutic approach. Meditsinskiy sovet = Medical Council. 2020;(12):60-63. (In Russ.) https://doi.org/10.21518/2079-701X-2020-12-60-63
Views:
842
Email this article 